Fig. 3: Characterization of EVs isolated by either Verita™ or differential ultracentrifugation.
From: Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test
a Distribution of particle sizes as determined by nanoparticle tracking analysis. Blue line represents the particle distribution from Verita™ isolation (N = 25 subjects) while the gray line represents the isolation from differential ultracentrifugation (N = 25 subjects). b Levels of residual contaminating total proteins based on Qubit™ protein assay (N = 25 subjects for each isolation methodology). The ability to differentiate cancer cases from controls based on biomarkers CA 19-9 and CA125 is shown for EVs isolated using the Verita™ isolation in panel (c), and EVs isolated by differential ultracentrifugation in panel (d). In both (c), (d) panels, the N for Controls is 11 subjects, and the N for Cancers is 14 subjects.
